Preclinical

Real-time imaging platform tracks labeled cells in animal models

30-Sep-2019 By Vassia Barba

In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.

Nordic Life Science Days

Brinter unveils ‘very versatile’ multi-material 3D bioprinter

26-Sep-2019 By Vassia Barba

Brinter recently introduced a multi-material ‘3D bioprinter’ to support biopharmaceutical research and development, including toxicity testing.

A-Alpha Bio raises $2.8m to solve ‘major problems’ in early-stage drug development: CEO

25-Sep-2019 By Melissa Fassbender

A-Alpha Bio raises $2.8m from venture capital firms and angel investors to further develop its technology – and initiate drug discovery and optimization partnerships with pharmaceutical companies.

Early manufacturing life-saving for biologics developers, says CMO exec

23-Sep-2019 By Vassia Barba

‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.

An arms race in drug development? AI demonstrates ‘true power’ to accelerate research

20-Sep-2019 By Melissa Fassbender

Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.

AI in drug development: ACRO, DIA, and Owkin to talk use cases and what comes next

18-Sep-2019 By Melissa Fassbender

There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...

O2h to do ‘heavy lifting’ as part of synthetic chemistry collaboration with Cedilla

17-Sep-2019 By Melissa Fassbender

Cedilla Therapeutics and o2h Discovery have announced a multi full-time-equivalent (FTE) expansion to their synthetic chemistry collaboration.

Sygnature’s new office a platform to launch US growth ‘campaign’

16-Sep-2019 By Melissa Fassbender

The drug discovery and preclinical services company has moved its US office to Kendall Square as it looks to ‘sustainably grow’ its US presence and increase sales in the coming years, says SVP.

Catalent adds to its clinical supply business with new facility

09-Sep-2019 By Vassia Barba

Catalent to invest $9m in the building of an early-stage clinical supply facility in San Diego, due to open in the summer of 2020, to integrate its CDMO business.

Structure data storage platform helps advance drug discovery

05-Sep-2019 By Vassia Barba

A cloud platform developed by Discngine aims to help drug developers manage their structural knowledge related to protein and ligand 3D structures.

People on the Move: Outsourcing-Pharma roundup August ‘19

04-Sep-2019 By Melissa Fassbender

The last month of summer saw several hires, including a lead for Worldwide Clinical Trials’ Japan operations, CEO appointments at CordenPharma and LabConnect, and Altasciences’ new CSO, who joins the company from Syneos.

Batavia eyes Horizon CHO cell tech to develop anti-Zika antibody

03-Sep-2019 By Melissa Fassbender

Batavia Biosciences signs a license agreement to use Horizon Discovery’s cell line expression system to produce a Zika virus-neutralizing antibody.

908 Devices launches a Rebel-lion in media analyzing

03-Sep-2019 By Vassia Barba

908 Devices launches Rebel, a bioprocess analyzer, enabling researchers to conduct their own cell culture media analysis to accelerate process development ‘by weeks’.

Organ-on-e-chip tech circumvents challenge of reading the heart's electrical patterns

26-Aug-2019 By Maggie Lynch

Researchers develop organ-on-an-electronic-chip platform to explore the electrophysiology of iPSC-derived cardiomyocytes and understand how the heart communicates.

Merck partners for ‘blockbuster’ vaccine target

26-Aug-2019 By Vassia Barba

Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.

Genecentric acquires Select to work on biomarker discovery

22-Aug-2019 By Vassia Barba

Genecentric’s immuno-oncology drug development solutions are bolstered through acquisition of Select Immunogenomics’ biomarker development services.

Researchers create miniature livers to support NASH R&D

20-Aug-2019 By Nick Taylor

Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.

Schrödinger extends drug discovery partnership with Morphic

20-Aug-2019 By Vassia Barba

Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.

Ex vivo 3D cell culture tech makes ‘true drug response prediction’ possible: Kiyatec

19-Aug-2019 By Maggie Lynch

Capital Health joins Kiyatec’s clinical trial to validate a patient-specific predictor test to improve response to cancer therapies for glioblastoma and anaplastic astrocytoma.

Heart-on-a-Chip can ‘confidently’ be used in drug discovery, development: CEO

16-Aug-2019 By Melissa Fassbender

Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.

Boehringer Ingelheim, MD Anderson launch virtual research and development center

13-Aug-2019 By Maggie Lynch

Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.

Prellis raises $10.5m to advance 3D tissue printing

12-Aug-2019 By Vassia Barba

Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.

C-Path and NORD collaborate to establish rare disease data platform

08-Aug-2019 By Maggie Lynch

The Critical Path Institute and National Organization for Rare Disorders are developing a new data and analytics platform to inform clinical trial design and advance therapies for rare diseases.

Takeda, Sosei partner to discover molecules in deal worth up to $1.2bn

06-Aug-2019 By Maggie Lynch

Takeda and Sosei both have a proud heritage in Japan and recently entered a billion-dollar partnership with Sosei to discover, develop, and commercialize molecules for patients in need around the world.

Novo Nordisk extends research collaboration with UK drug discovery firm

05-Aug-2019 By Vassia Barba

Novo Nordisk and e-therapeutics will use the latter’s genomics technology platform to analyse data from diabetes patients.

Caprion and HistoGeneX form joint company offering new services, greater global reach

05-Aug-2019 By Maggie Lynch

Caprion Biosciences and HistoGeneX join forces, combining the two businesses to provide a source for immune monitoring, protein characterization, and tissue pathology solutions, as immunotherapy landscape evolves.

People on the Move: Outsourcing-Pharma roundup July ‘19

02-Aug-2019 By Melissa Fassbender

CordenPharma has a new CEO, Arbour Group advances plans to expand in RTP, Ashfield brings on a former Iqvia VP, and Recursion adds to its c-suite after raising $121m this month.

Taconic launches preconditioned NASH mice to accelerate clinical development

01-Aug-2019 By Vassia Barba

Aiming to speed up and facilitate the clinical development of liver failure treatments, Taconic launches the first commercially available diet-induced NASH rodent model.

Iqvia sees ‘a lot of runway ahead’ despite growth in Q2

30-Jul-2019 By Maggie Lynch

Iqvia is looking to the future and opportunities in AI, after reporting $2.74bn in revenue for Q2 FY19.

ClinOne lauching direct-to-patient recruitment platform in 2020

29-Jul-2019 By Vassia Barba

ClinOne is launching a direct-to-patient recruitment platform, which will initially be offered at no cost to sponsors for the first year.

Bioscience incubator to be built in Illinois to support growing Midwest hub

25-Jul-2019 By Maggie Lynch

Rosalind Franklin University of Medicine and Science opens its incubator, Helix 51, creating wet lab and research space for the Illinois bioscience hub.

Biofourmis study uses wearables to improve patient centricity in heart failure trials

25-Jul-2019 By Vassia Barba

A study by Biofourmis aims to improve patient centricity in the drug approval processes by using wearable technology and mobile software to monitor the quality of life for patients with heart failure.

Gotham, Mercachem create molecule library for RNA-modifying drug discovery

22-Jul-2019 By Vassia Barba

A collaboration between Mercachem and Gotham leads to the generation of a molecule library, expected to enable new discovery opportunities in the epitranscriptomic targets space.

Lovelace, Exemplar to work on Sickle Cell Disease model under NIH contract

22-Jul-2019 By Vassia Barba

Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.

‘Upper echelons of administration’ recognize need for growth in kidney disease treatments

19-Jul-2019 By Maggie Lynch

An Executive Order signed by President Trump aims to increase research, incentives, and treatment access for kidney disease patients and could 'fundamentally transform kidney therapeutics,' says president of the American Society of Nephrology....

Mission Bio brings single-cell genomics offering to China

16-Jul-2019 By Melissa Fassbender

Novogene is working with Mission Bio to offer customers in China access to the Tapestri Platform, which is being used in the drug development process by LabCorp and more than a dozen institutions.

AI-enabled platform secures $121m to 'spearhead' NCE discovery, predictive pharmacology

15-Jul-2019 By Melissa Fassbender

Recursion Pharmaceuticals plans to partner with big pharma on rare disease programs after raising $121m to build out its machine learning-enabled platform, which draws on an in-house developed dataset to support drug discovery and development.

Outsourced drug discovery market to top $68bn in 2028

12-Jul-2019 By Maggie Lynch

The global drug discovery market is expected to reach $68bn in 2028, according to a Visiongain report, with revenue gains driven by flexibility, agility, and the ability to innovate, says Evotec executive.

As ‘transformational’ as the internet: Alten adds blockchain initiative

11-Jul-2019 By Maggie Lynch

Alten Calsoft Labs launches its first initiative for blockchain through its scalable clinical trial platform BioPharma Ledger to address life sciences processes using BlockApps middleware.

‘Increasing visibility’: Repositive relaunches Cancer Models platform with accessible directory

11-Jul-2019 By Maggie Lynch

Repositive ‘increases visibility’ while ‘maintaining confidentiality’ as it makes its directory of preclinical cancer models publicly browsable as part of the relaunch of its Cancer Models Platform.

Charles River to open flexible vivarium space in San Francisco

11-Jul-2019 By Melissa Fassbender

The new lab will provide customers with 'low cost, turnkey' vivarium space in addition to various in vivo support services.

Emergex develops synthetic hand-foot-and-mouth vaccine

10-Jul-2019 By Vassia Barba

In collaboration with a research center, Emergex will apply its synthetic development approach on a vaccine against hand, foot and mouth disease.

StemoniX opens California site to focus on microOrgan research platform

09-Jul-2019 By Maggie Lynch

StemoniX opens a new facility in California to house its research team working on its high-throughput microOrgan technology platforms for drug discovery and preclinical development.

Merck and Biogen both tap Skyhawk’s RNA technology platform

09-Jul-2019 By Maggie Lynch

Skyhawk enters an agreement with Merck to discover and develop small molecules to modulate RNA splicing, and expands its existing development agreement with Biogen.

Instem receives grant, enters consortium to mitigate late stage risks

08-Jul-2019 By Maggie Lynch

Notocord, an Instem company, will provide data acquisition and analysis services to a research and innovation program to improve risk prediction of cardiovascular adverse events.

Pharma with 'AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says report

08-Jul-2019 By Melissa Fassbender

Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Evotec are among the top companies with “AI-friendly” CEOs, according to a report, which suggests that these businesses will prosper driven by a more effective application of AI.

How to reduce the odds of failure in late phase clinical trials

05-Jul-2019 By Melissa Fassbender

Improving the prognostic value of early phase data is among one of several ways to increase the probability of successes in drug development, a process which has become more expensive as failure rates have risen, says an industry expert.

Evotec signs novel antibiotics research deal with Nosopharm

04-Jul-2019 By Melissa Fassbender

Evotec is collaborating with Nosopharm, which expects to launch first-in-human studies in 2021, to accelerate the development of novel antibiotics.

Lovelace awarded $20m contract with NIH to lead disease model research collaboration

04-Jul-2019 By Maggie Lynch

Lovelace Biomedical leads a collaboration with The Jackson Laboratory, Exemplar Genetics, Iontox, and the University of Pennsylvania as part of a $20m contract with the NIH.